Evonik Evonik

X
menu

    Market Place

    Market Place

    Post Enquiry

    Post Enquiry
    menu
    [{"orgOrder":0,"company":"Neurosterix","sponsor":"Perceptive Xontogeny Venture Fund II","pharmaFlowCategory":"D","amount":"$63.0 million","upfrontCash":"Undisclosed","newsHeadline":"Neurosterix Launches with $63M to Advance Allosteric Modulator Therapeutics for Neurological Disorders","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Preclinical","country":"SWITZERLAND","productType":"Small molecule","productStatus":"New Molecular Entity","date":"April 2024","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Preclinical"}]

    Find Clinical Drug Pipeline Developments & Deals by Neurosterix

    Menu

    Neurosterix

    EVENTS

    • Webinars & Exhibitions

    PRESENTATION(s)

    VIDEO(s)

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass
    Loading...

    All Data

    Previous
    Next
    Filters Filter
    ×
    FILTER:
    filter Company
      filter Sponsor
        filter Country
          filter Therapeutic Area
            filter Study Phase

              Active Filter(s):

              refreshFilters
              refreshReset Filter
              refresh Reset Filter
              price-trend All Developments

              Companies By Therapeutic Area

              Development Status

              Neurosterix

              Contact Supplier
              • Deals
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag Switzerland
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              Neurosterix Launches with $63M to Advance Allosteric Modulator Therapeutics for Neurological Disorders

              Details:

              The financing aims to fund the clinical development of Neurosterix’s lead program, which is a muscarinic acetylcholine receptor subtype 4 positive allosteric modulators for the treatment of patients suffering from schizophrenia.

              Lead Product(s): Undisclosed

              Therapeutic Area: Psychiatry/Psychology Product Name: Undisclosed

              Highest Development Status: Preclinical Product Type: Small molecule

              Partner/Sponsor/Collaborator: Perceptive Xontogeny Venture Fund II

              Deal Size: $63.0 million Upfront Cash: Undisclosed

              Deal Type: Series A Financing April 03, 2024

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity
              Minakem offers CDMO services for API & HPAPI, generics, regulatory expertise, track record performance & FDA & GMP certifications.
              Temad- We think of world-class quality.
              Post Enquiry
              POST ENQUIRY